Korro Bio
MA - CambridgeBiotechnology
Focus: Korro Bio is an early-stage biotechnology company founded in 2024 focused on RNA-editing drugs targeting oncology and gene therapy indications. The company is pre-revenue and currently executing a single clinical program.
Profile data last refreshed 18h ago · AI intelligence enriched 2w ago
Open Jobs
3-2 this month
Stable — net -2 jobs in 30d
2 added, 4 removed. Backfill posture.
Should You Work at Korro Bio?
AI assessmentHigh-risk, high-reward early-stage play suitable only for risk-tolerant scientists seeking equity upside and technical influence over stability.
Why Work Here
- Ground-floor opportunity at a newly founded RNA-editing platform company with differentiated technology in a high-growth modality
- Early-stage environment offers broad role scope and accelerated career progression before organizational structure solidifies
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
KRRO-110
Alpha-1 Anti-trypsin DeficiencyClinical Trials (1)
NCT06677307A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110
Phase 1/2Help build intelligence for Korro Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.